Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingyan Dripping Pills (清咽滴丸) is a traditional Chinese medicine (TCM) herbal formulation developed and manufactured by Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited. It is specifically indicated for the treatment of various throat conditions, including acute and chronic pharyngitis, sore throat, dry throat, and red, swollen pharynx. The medication is produced using a specialized pharmaceutical technique where herbal extracts are thermally blended with excipients and solidified into droplets (dripping pills). Pharmacological research has identified key bioactive components such as borneol and menthol, which contribute to its anti-inflammatory and analgesic properties. During the COVID-19 pandemic, the formulation was recommended by the National Health Commission of the People's Republic of China for the symptomatic relief of throat-related issues, with studies suggesting potential anti-SARS-CoV-2 activity among its bioactive compounds.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qingyan Dripping Pills.